Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
Chemical and physical data | |
Formula | C16H25N3O3 |
Molar mass | 307.394 g·mol−1 |
3D model (JSmol) | |
|
Lys-MDA (Lysine-MDA, N-(L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative with empathogenic effects, which acts as a prodrug for MDA with a slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.[1][2][3][4]
Phenylalkyl- amines (other than cathinones) |
|
---|---|
Cyclized phenyl- alkylamines | |
Cathinones | |
Tryptamines | |
Chemical classes |